By the end of this summer, the Food and Drug Administration
is (once again) expected to decide on whether or not to allow the first
“pink Viagra” pills to be marketed in the United States. This will
be the third time that the drug, flibanserin, has been brought before
the FDA since 2010, when its approval was unanimously voted against by
the agency.
Nicknames can be misleading.
Who hasn’t heard of Viagra, right?...
